Expert Interviews

With a population goal of having 80% to 90% of age-eligible Americans screened for colorectal cancer, colonoscopy can not be the initial test for everyone, Fendrick emphasizes.

Never considered the carbon footprint left by a screening for colorectal cancer? Fendrick has and did the research to learn more. He explains in this short video.

ACOG 2025: Laxmi Gannu, MS, discusses key findings from a provider survey on postpartum depression screening practices, training gaps, and referral patterns.

Johanna Finkle, MD, outlines how clinicians can adapt weight management counseling during key stages of a woman’s life, from preconception through menopause.

A panelist discusses how education about anaphylaxis recognition, early epinephrine administration, and addressing barriers like device portability remains crucial, with intranasal epinephrine potentially solving many existing challenges in anaphylaxis management.

A panelist discusses how real-world cases demonstrate both the effectiveness of epinephrine when properly administered and the importance of ensuring patients actually carry their medication, through the stories of a college student with cashew allergy and a child undergoing a peanut challenge.

A panelist discusses how Neffy offers significant advantages over traditional autoinjectors including longer shelf life (24-30 months), better temperature tolerance, and needle-free administration that addresses several unmet needs in anaphylaxis management.

ACOG 2025: Joy Baker, MD, urged primary care clinicians to screen early, refer confidently, and help change the statistics on maternal mental health.

A panelist discusses how the current anaphylaxis grading system classifies reactions from zero (no reaction) to four (death), with grade two representing moderate but significantly uncomfortable symptoms affecting multiple body systems.

A panelist discusses how the newly FDA-approved intranasal epinephrine (Neffy) delivers blood concentrations and physiological responses comparable or superior to traditional intramuscular epinephrine administration methods.

A panelist discusses how current guidance has evolved to no longer require emergency department visits for all epinephrine uses, particularly when patients experience prompt and complete resolution of symptoms after administration.

A panelist discusses how patient uncertainty about when to administer epinephrine and reluctance to use autoinjectors are major barriers to timely treatment, with over 40% not filling their prescriptions and 55-60% not consistently carrying their devices.

ACOG 2025: Johanna Finkle, MD, shares strategies to start weight conversations with patients and build clinician confidence in counseling and treatment options.

A panelist discusses how epinephrine is definitively the first-line treatment for anaphylaxis regardless of severity, emphasizing that delayed administration is associated with poor outcomes including abnormal vital signs and increased risk of hospitalization.

A panelist discusses how anaphylaxis should be defined and treated promptly with epinephrine, highlighting the concerning statistic that not all patients who experience anaphylaxis receive this critical first-line treatment.

ACOG 2025: Joy Baker, MD, discusses the importance of listening closely to how patients describe postpartum distress—and to read between the lines.

ACOG 2025: The Junonia study was designed to understand gaps in care for women with PPD using surveys of their clinicians and care coordinators.

The nonhormonal neurokinin-3 receptor antagonist improved menopausal adiposity without appreciable impact on body weight or BMI, Santoro explained at 2025 ACOG meeting.

ACOG 2025: Pregnant patients may not want to discuss weight gain initially, so focus on overall perinatal health, and use that information to guide more conversation.

LeThenia Joy Baker, MD, explains why PPD is often overlooked compared to physical pregnancy conditions like gestational diabetes.

ACOG 2025: Dr Baker shares how language can help create a trusting space for patients to speak openly about postpartum depression.

ACOG 2025: Joy Baker, MD, called for stronger cross-specialty collaboration to address maternal mental health after birth.

The two areas where primary care physicians can contribute to improving women's health, according to Laurence Shields, MD.

Building trust with patients early on will help them feel comfortable discussing their symptoms and treatment preferences, says JoAnn Pinkerton, MD.

A panelist discusses how simplifying treatment regimens, using nonsteroidal options, and fostering collaboration between primary care and dermatology can improve patient adherence and outcomes while emphasizing the importance of careful consideration when transitioning to systemic treatments or biologics due to safety concerns and patient needs.

A panelist discusses how the ADORING trial for tapinarof demonstrated good efficacy and safety, but emphasizes that treatment choices for atopic dermatitis depend on patient needs, preferences, and the specific characteristics of their condition, with factors like speed of action, safety, and adherence playing key roles in decision-making.

A panelist discusses how the real-world use of crisaborole, roflumilast, and ruxolitinib for atopic dermatitis reveals differing tolerability and efficacy, with roflumilast standing out for its superior results and ease of use while ruxolitinib is limited by safety concerns for larger areas of the body.

The speaker discusses the challenges of treating patients with topical steroid withdrawal, emphasizing the need for careful steroid reintroduction and responsible use while also exploring newer nonsteroidal treatments for atopic dermatitis and the barriers to access due to high costs and limited comparative effectiveness data.